ZRZaigham Abbas Rizvi

Zaigham Abbas Rizvi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zaigham Abbas Rizvi has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Awasthi

    Immunology Core Laboratory Translational Health Science and Technology Institute Faridabad India

    11 shared publications
  • Srikanth Sadhu

    Immuno-biology Lab, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, Haryana, India

    8 shared publications
  • Manas Ranjan Tripathy

    Immuno-biology Lab, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, Haryana, India

    6 shared publications
  • Madhu Dikshit

    CSIR-Central Drug Research Institute

    5 shared publications
  • Sweety Samal

    Infection and Immunology Centre, Translational Health Science and Technology Institute NCR‐Biotech Science Cluster Faridabad Haryana India

    5 shared publications
  • Jyotsna Dandotiya

    Immuno‐biology Lab, Infection and Immunology Centre, Translational Health Science and Technology Institute NCR‐Biotech Science Cluster Faridabad Haryana India

    4 shared publications

Latest Publications

  • Kyasanur Forest Disease: Advances in Experimental Animal Models, Immune Assays, and Challenges in Vaccine Development

    by Sahina Sidhik, Zaigham Abbas Rizvi, Amit Awasthi

    Kyasanur Forest Disease (KFD) is a tick‐borne viral haemorrhagic fever endemic to forested regions of South India, with case fatality rates ranging from 3% to 10% and seasonal outbreaks causing recurrent illness among at‐risk populations such as forest workers and villagers. The historically used formalin‐inactivated KFD vaccine showed limited effectiveness in field studies, providing only about 62% protection. This moderate level of protection highlights the need for improved vaccines that offer higher efficacy and longer‐lasting immunity for populations living in endemic areas. A major challenge in vaccine development is the limited understanding of immune responses that protect against KFD, along with the lack of preclinical models that fully reflect the disease as it occurs in humans. Existing animal models—including murine systems and limited non‐human primate studies ‐have contributed to understanding viral replication, lethality, viraemia kinetics, and basic immunological responses. However, murine models often fail to reproduce the full spectrum of human immunopathology, particularly haemorrhagic manifestations and complex host immune responses, while non‐human primate models remain limited by cost, accessibility, and incomplete characterisation. Furthermore, variability in experimental endpoints and the absence of standardized immunogenicity and neutralisation assays restrict cross‐study comparability and hinder identification of immune correlates of protection. This review critically synthesises current knowledge on KFD animal models and host immune responses, identifying key gaps in translational relevance. We propose a prioritised roadmap that includes: (i) development and validation of advanced preclinical models that better mimic human disease progression and immune dysregulation; (ii) systematic identification of serological and cellular correlates of protection; and (iii) standardisation of virological, serological, and immunological assays to support regulatory evaluation and vaccine benchmarking. Addressing these challenges through coordinated interdisciplinary efforts will accelerate the development of next‐generation KFD vaccines and therapeutics tailored to endemic populations.


  • Open Access

    Corrigendum: Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions

    by Zaigham Abbas Rizvi, Prabhakar Babele, Upasna Madan, Srikanth Sadhu, Manas Ranjan Tripathy, Sandeep Goswami, Shailendra Mani, Madhu Dikshit, Amit Awasthi

    PAGE \* Arabic \* MERGEFORMAT 3In the published article, there was an error in [Figure 5D (FACS panel of Th0 & Th2)] as published. [The FACS images in Figure 5D (Th0 & Th2 panel) were originally generated by Upasna Madan, a graduate student, as part of a broader project investigating the in vitro immunomodulatory effects of eight herbal extracts. Initially, all experiments were conducted with multiple biological and technical replicates, intending to publish the findings in a single manuscript. However, during analysis, we determined that presenting the data in multiple manuscripts, each focusing on a specific herbal extract, would be more effective.During this segmentation process, representative control images from the FACS analysis were inadvertently reused in two different manuscripts (PMID: 36960064 & PMID: 37765142). Since each experiment included multiple control replicates, we are in the process of replacing the affected control FACS plots. Importantly, as these FACS plots pertain only to control conditions, their replacement does not alter the overall findings, interpretations, or conclusions of either manuscript].The corrected [Figure 5D, Th0 & Th2 panel] and its caption

  • SARS‐CoV‐2 infection induces thymic atrophy mediated by IFN‐γ in hACE2 transgenic mice

    by Zaigham Abbas Rizvi, Srikanth Sadhu, Jyotsna Dandotiya, Puja Sharma, Akshay Binayke, Virendra Singh, Vinayaka Das, Ritika Khatri, Rajesh Kumar, Sweety Samal, et al.

    Pathogenic infections cause thymic atrophy, perturb thymic T‐cell development, and alter immunological response. Previous studies reported dysregulated T‐cell function and lymphopenia in coronavirus disease‐19 (COVID‐19). However, immunopathological changes in the thymus associated with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection have not been elucidated. Here, we report that SARS‐CoV‐2 infects thymocytes, and induces CD4+CD8+ (double positive; DP) T‐cell apoptosis leading to thymic atrophy and loss of peripheral TCR repertoire in K18‐hACE2 transgenic mice. Infected thymus led to increased CD44+CD25− T‐cells, indicating an early arrest in the T‐cell maturation pathway. Thymic atrophy was notably higher in male hACE2‐Tg mice than in females and involved an upregulated de‐novo synthesis pathway of thymic glucocorticoid. Further, IFN‐γ was crucial for thymic atrophy, as anti‐IFN‐γ ‐antibody neutralization blunted thymic involution. Therapeutic use of Remdesivir also rescued thymic atrophy. While the Omicron variant and its sub‐lineage BA.5 variant caused marginal thymic atrophy, the delta variant of SARS‐CoV‐2 exhibited severe thymic atrophy characterized by severely depleted DP T‐cells. Recently characterized broadly SARS‐CoV‐2 neutralizing monoclonal antibody P4A2 was able to rescue thymic atrophy and restore the thymic maturation pathway of T‐cells. Together, we report SARS‐CoV‐2‐associated thymic atrophy resulting from impaired T‐cell maturation pathway which may contribute to dyregulated T cell response during COVID‐19.


  • Open Access

    Evaluation of Ayush-64 (a Polyherbal Formulation) and Its Ingredients in the Syrian Hamster Model for SARS-CoV-2 Infection Reveals the Preventative Potential of Alstonia scholaris

    by Zaigham Abbas Rizvi, Upasna Madan, Manas Ranjan Tripathy, Sandeep Goswami, Shailendra Mani, Amit Awasthi, Madhu Dikshit

    In the current study, we evaluated the efficacy of Ayush-64 (A64), a polyherbal formulation containing Alstonia scholaris (L.) R. Br. (A. scholaris), Caesalpinia crista L. (C. crista), Picrorhiza kurroa Royle ex Benth (P. kurroa), and Swertia chirata (Roxb.) H. Karst. (S. chirata) against COVID-19 in a Syrian hamster infection model. Preventative use of A64 resulted in the late-phase recovery of body weight loss in severe acquired respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected hamsters, suppression of pro-inflammatory cytokines, and blunted pulmonary pathology. In addition, we also investigated the efficacy of individual ingredients of A64, viz., A. scholaris, C. crista, P. kurroa, and S. chirata, in the hamster model. The hamster challenge data showed robust anti-viral and immunomodulatory potential in A. scholaris, followed by P. kurroa. However, C. crista and S. chirata of A64 showed prominent immunomodulatory potential without limiting the lung viral load. In order to better understand the immunomodulatory potential of these herbal extracts, we used an in vitro assay of helper T cell differentiation and found that A. scholaris mediated a more profound suppression of Th1, Th2, and Th17 cell differentiation as compared to A64 and other ingredients. Taken together, our animal study data identifies the ameliorative potential of A64 in mitigating coronavirus disease-19 (COVID-19) pulmonary pathology. A. scholaris, a constituent extract of A64, showed relatively higher anti-viral and immunomodulatory potential against COVID-19. The present study warrants further investigations to identify the active pharmaceutical ingredients of A. scholaris for further studies.


  • Open Access

    Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice

    by Zaigham Abbas Rizvi, Jyotsna Dandotiya, Srikanth Sadhu, Ritika Khatri, Janmejay Singh, Virendra Singh, Neeta Adhikari, Kritika Sharma, Vinayake Das, Amit Kumar Pandey, et al.

    A recently emerged sub-lineage of Omicron, BA.5, together with BA.4, caused a fifth wave of coronavirus disease (COVID-19) in South Africa and subsequently emerged as a predominant strain globally due to its high transmissibility. The lethality of BA.5 infection has not been studied in an acute hACE2 transgenic (hACE2.Tg) mouse model. Here, we investigated tissue-tropism and immuno-pathology induced by BA.5 infection in hACE2.Tg mice. Our data show that intranasal infection of BA.5 in hACE2.Tg mice resulted in attenuated pulmonary infection and pathology with diminished COVID-19-induced clinical and pathological manifestations. BA.5, similar to Omicron (B.1.1.529), infection led to attenuated production of inflammatory cytokines, anti-viral response and effector T cell response as compared to the ancestral strain of SARS-CoV-2, Wuhan-Hu-1. We show that mice recovered from B.1.1.529 infection showed robust protection against BA.5 infection associated with reduced lung viral load and pathology. Together, our data provide insights as to why BA.5 infection escapes previous SARS-CoV-2 exposure induced-T cell immunity but may result in milder immuno-pathology and alleviated chances of re-infectivity in Omicron-recovered individuals.


  • Open Access

    Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions

    by Zaigham Abbas Rizvi, Prabhakar Babele, Upasna Madan, Srikanth Sadhu, Manas Ranjan Tripathy, Sandeep Goswami, Shailendra Mani, Madhu Dikshit, Amit Awasthi

    Cytokine release syndrome (CRS) due to severe acute respiratory coronavirus-2 (SARS-CoV-2) infection leads to life-threatening pneumonia which has been associated with coronavirus disease (COVID-19) pathologies. Centuries-old Asian traditional medicines such as Withania somnifera (L.) Dunal (WS) and Tinospora cordifolia (Willd.) Miers (TC) possess potent immunomodulatory effects and were used by the AYUSH ministry, in India during the COVID-19 pandemic. In the present study, we investigated WS and TC’s anti-viral and immunomodulatory efficacy at the human equivalent doses using suitable in vitro and in vivo models. While both WS and TC showed immuno-modulatory potential, WS showed robust protection against loss in body weight, viral load, and pulmonary pathology in the hamster model of SARS-CoV2. In vitro pretreatment of mice and human neutrophils with WS and TC had no adverse effect on PMA, calcium ionophore, and TRLM-induced ROS generation, phagocytosis, bactericidal activity, and NETs formation. Interestingly, WS significantly suppressed the pro-inflammatory cytokines-induced Th1, Th2, and Th17 differentiation. We also used hACE2 transgenic mice to further investigate the efficacy of WS against acute SARS-CoV2 infection. Prophylactic treatment of WS in the hACE2 mice model showed significant protection against body weight loss, inflammation, and the lung viral load. The results obtained indicate that WS promoted the immunosuppressive environment in the hamster and hACE2 transgenic mice models and limited the worsening of the disease by reducing inflammation, suggesting that WS might be useful against other acute viral infections. The present study thus provides pre-clinical efficacy data to demonstrate a robust protective effect of WS against COVID-19 through its broader immunomodulatory activity


  • Open Access

    Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis

    by Zaigham Abbas Rizvi, Prabhakar Babele, Srikanth Sadhu, Upasna Madan, Manas Ranjan Tripathy, Sandeep Goswami, Shailendra Mani, Sachin Kumar, Amit Awasthi, Madhu Dikshit

    Severe coronavirus disease (COVID-19) is accompanied with acute respiratory distress syndrome & pulmonary pathology, and is presented mostly with inflammatory cytokine release, dysregulated immune response, skewed neutrophil/ lymphocyte ratio, and hypercoagulable state. Though vaccinations have proved effective in reducing the COVID-19 related mortality, the limitation of use of vaccine against immunocompromised, comorbidity, and emerging variants remains a concern. In the current study we investigate for the first-time the efficacy of Glycyrrhiza glabra (GG) extract, a potent immunomodulator, against SARS-CoV-2 infection in hamsters. Prophylactic treatment with GG showed protection against loss in body weight and 35-40% decrease in lung viral load along with reduced lung pathology in the hamster model. Remarkably, GG reduced the mRNA expression of pro-inflammatory cytokines and Plasminogen activator inhibito-1 (PAI-1). In-vitro , GG acted as potent immunomodulator by reducing Th2 and Th17 differentiation and IL-4 and IL-17A cytokine production. In addition, GG also showed robust potential to suppress ROS, mtROS and NETs generation in a concentration dependent manner in both human polymorphonuclear neutrophils (PMNs) and murine bone marrow derived neutrophils (BMDNs). Taken together, we provide evidence for the protective efficacy of GG against COVID-19 and its putative mechanistic insight, which might be developed as a future immunomodulatory approach against various pathologies with high cytokine production, aberrant neutrophil activation including coronavirus infection.


  • Open Access

    SARS-CoV-2 and its variants, but not Omicron, induces thymic atrophy and impaired T cell development

    by Zaigham Abbas Rizvi, Srikanth Sadhu, Jyotsna Dandotiya, Akshay Binyka, Puja Sharma, Virendra Singh, Vinayaka Das, Ritika Khatri, Rajesh Kumar, Sweety Samal, et al.

    Pathogenic infections cause thymic atrophy, perturb thymic-T cell development and alter immunological response. Previous studies reported dysregulated T cell function and lymphopenia in coronavirus disease-19 (COVID-19) patients. However, immune-pathological changes, in the thymus, post severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection have not been elucidated. Here, we report SARS-CoV-2 infects thymocytes, depletes CD4+CD8+ (double positive; DP) T cell population associated with an increased apoptosis of thymocytes, which leads to severe thymic atrophy in K18-hACE2-Tg mice. CD44+CD25-T cells were found to be enriched in infected thymus, indicating an early arrest in the T cell developmental pathway. Further, Interferon gamma (IFN-γ) was crucial for thymic atrophy, as anti-IFN-γ antibody neutralization rescued the loss of thymic involution. Therapeutic use of remdesivir (prototype anti-viral drug) was also able to rescue thymic atrophy. While Omicron variant of SARS-CoV2 caused marginal thymic atrophy, delta variant of SARS-CoV-2 exhibited most profound thymic atrophy characterized by severely depleted DP T cells. Recently characterized broadly SARS-CoV-2 neutralizing monoclonal antibody P4A2 was able to rescue thymic atrophy and restore thymic developmental pathway of T cells. Together, we provide the first report of SARS-CoV-2 associated thymic atrophy resulting from impaired T cell developmental pathway and also explains dysregulated T cell function in COVID-19.


  • Open Access

    Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection

    by Zaigham Abbas Rizvi, Rajdeep Dalal, Srikanth Sadhu, Akshay Binayke, Jyotsna Dandotiya, Yashwant Kumar, Tripti Shrivastava, Sonu Kumar Gupta, Suruchi Aggarwal, Manas Ranjan Tripathy, et al.

    Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the Golden Syrian hamster causes lung pathology that resembles human coronavirus disease (COVID-19). However, extrapulmonary pathologies associated with SARS-CoV-2 infection and post-COVID sequelae remain to be understood. Here, we show, using a hamster model, that the early phase of SARS-CoV-2 infection leads to an acute inflammatory response and lung pathologies, while the late phase of infection causes cardiovascular complications (CVCs) characterized by ventricular wall thickening associated with increased ventricular mass/body mass ratio and interstitial coronary fibrosis. Molecular profiling further substantiated our findings of CVC as SARS-CoV-2-infected hamsters showed elevated levels of serum cardiac troponin I, cholesterol, low-density lipoprotein, and long-chain fatty acid triglycerides. Serum metabolomics profiling of SARS-CoV-2-infected hamsters identified N-acetylneuraminate, a functional metabolite found to be associated with CVC, as a metabolic marker was found to be common between SARS-CoV-2-infected hamsters and COVID-19 patients. Together, we propose hamsters as a suitable animal model to study post-COVID sequelae associated with CVC, which could be extended to therapeutic interventions.


  • Open Access

    High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity

    by Zaigham Abbas Rizvi, Rajdeep Dalal, Srikanth Sadhu, Yashwant Kumar, Shakti Kumar, Sonu Kumar Gupta, Manas Ranjan Tripathy, Deepak Kumar Rathore, Amit Awasthi

    Salt triggers tumor immunity through microbiota-mediated NK cell activation.